{"id":12459,"date":"2003-12-01T06:04:32","date_gmt":"2003-12-01T06:04:32","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=12459"},"modified":"2014-05-27T10:29:58","modified_gmt":"2014-05-27T10:29:58","slug":"five-year-results-of-kaletra-based-therapy-in-treatment-naive-hiv-patients","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/12459","title":{"rendered":"Five-year results of Kaletra-based therapy in treatment-na\u00efve HIV patients"},"content":{"rendered":"<p><strong>HIVandHepatitis.com<\/strong><\/p>\n<p><strong>Antiretroviral regimens have demonstrated potent virologic and CD4 responses, but longer-term data are needed to evaluate the durability of these responses.<\/strong><\/p>\n<p>One hundred antiretroviral-na\u00efve patients received one of three doses of Kaletra (lopinavir\/ritonavir, LPV\/r) with d4T and 3TC twice-daily. After 48 weeks, all patients received LPV\/r 400\/100 mg twice-daily with d4T and 3TC.<\/p>\n<p>Median baseline HIV viral load and CD4 count were 4.9 log10 copies\/mL and 338 cells\/mm3 respectively. Prior to week 252, 32 patients discontinued study therapy due to adverse events (13%) or other reasons [loss to follow-up, nonadherence, personal reasons (19%)].<\/p>\n<p>At year five (week 252), 67\/68 (observed data, 99%) and 67\/100 (intent-to-treat, 67%) had viral load &lt;400 copies\/mL. The only HIV RNA measurement &gt;400 copies\/mL at year five occurred during a lengthy treatment interruption.<\/p>\n<p>Through five years, no PI-associated mutations have been observed in patients with virologic failure.<\/p>\n<p>Median CD4 increase from baseline to week 252 was 505 cells\/mm3 among patients continuing therapy. The most common drug-related moderate\/severe side effects through week 252 were diarrhoea (28%), nausea (16%), abdominal pain (10%), and asthenia (9%).<\/p>\n<p>Sixteen and 13 patients initiated lipid-lowering agents (LLA) with total cholesterol &gt;240 mg\/dL or triglycerides &gt;400 mg\/dL (measured without regard to fasting); from LLA initiation to the final value available through week 252, total cholesterol and triglycerides decreased by a median of 24% and 32%, respectively.<\/p>\n<p>The statins used were pravastatin in 11 patients, atorvastatin in nine, and four received both; nine patients used a fibrate, eight of them fenofibrate. Three patients used both a statin and a fibrate. Initiation of lipid-lowering therapy was at the discretion of the investigator and was not study defined.<\/p>\n<p>\u201cLipid elevations are relatively common with lopinavir\/ritonavir,\u201d commented Dr Hicks, \u201cbut the most important piece of information here is that standard lipid-lowering therapy can have a pretty good impact, at least in this small subset of patients.\u201d<\/p>\n<p>LPV\/r-based therapy demonstrates sustained antiretroviral activity and is generally well tolerated in ARV-na\u00efve patients through five years of therapy. Decreases in total cholesterol and triglycerides were observed in patients initiating lipid-lowering agents.<\/p>\n<p>Reference:<\/p>\n<p>Hicks C, Da Silva B, King KR et al. 5-year results of lopinavir\/ritonavir (lpv\/r)-based therapy in antiretroviral-naive HIV-infected patients. 9th EACS, Warsaw. 25-29 October 2003. Abstract 7.3\/16.<br \/>\n<a href=\"http:\/\/www.aegis.org\/conferences\/eacs\/2003\/165.html\">http:\/\/www.aegis.org\/conferences\/eacs\/2003\/165.html<\/a><\/p>\n<p><strong>\u00a9 Copyright 2003 by HIV and Hepatitis.com. All Rights Reserved. Reproduction for personal or educational use is encouraged and does not require permission. Written permission is required to re-print copyrighted articles but is almost always granted (email <a href=\"mailto:publisher@HIVandHepatitis.com\">publisher@HIVandHepatitis.com<\/a>).<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>HIVandHepatitis.com Antiretroviral regimens have demonstrated potent virologic and CD4 responses, but longer-term data are needed to evaluate the durability of these responses. One hundred antiretroviral-na\u00efve patients received one of three doses of Kaletra (lopinavir\/ritonavir, LPV\/r) with d4T and 3TC twice-daily. &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,3],"tags":[75],"class_list":["post-12459","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-antiretrovirals","tag-eacs-9th-2003"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/12459","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=12459"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/12459\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=12459"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=12459"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=12459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}